Physician profile
Robert Mcmahon
NPI 1093775801
$10,078.55
in general payments reported to CMS, 2019-2025
50 companies · $2,261 in 2025
The $2,261 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $1,129 · 2021: $16.85 · 2022: $1,135 · 2023: $1,774 · 2024: $2,110 · 2025: $2,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,144.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.62 | 2022-2025 | |
| Allergan, INC. | $1,106.52 | 2019-2022 | |
| Biogen, INC. | $638.23 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Celgene Corporation | $501.26 | 2023-2025 | Zeposia |
| Lundbeck LLC | $497.53 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $477.86 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $425.01 | 2019-2025 | |
| Emd Serono, INC. | $304.72 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $300.39 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $290.75 | 2020-2025 | |
| Argenx US, INC. | $273.66 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $259.63 | 2022-2025 | |
| Tg Therapeutics, INC. | $243.80 | 2023-2025 | |
| Lilly USA, LLC | $235.97 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $212.90 | 2019-2025 | Ultomiris |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $203.25 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $192.30 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $186.02 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Greenwich Biosciences, INC. | $134.91 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $133.66 | 2020-2025 | Acthar |
| Merz North America, INC. | $121.71 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $121.56 | 2024-2025 | Xeomin, Inbrija |
| Jazz Pharmaceuticals INC. | $121.23 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $108.48 | 2019-2022 | |
| Livanova USA, INC. | $107.46 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $103.57 | 2019-2024 | Nourianz |
| Neurelis, INC. | $96.30 | 2022-2025 | Valtoco |
| Acorda Therapeutics, INC | $94.20 | 2019-2023 | Inbrija, Ampyra |
| Csl Behring | $82.88 | 2022-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $81.06 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $80.96 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $78.74 | 2022-2023 | Aimovig |
| Astrazeneca Pharmaceuticals Lp | $76.55 | 2024-2025 | Wainua |
| Grifols USA, LLC | $68.20 | 2019-2023 | Gamunex-C |
| Mdd US Operations, LLC | $64.28 | 2023-2024 | Gocovri, Gocovri |
| Genzyme Corporation | $61.33 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $57.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $48.70 | 2024-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $42.22 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $36.69 | 2025 | Ponvory |
| Medtronic, INC. | $34.41 | 2022 | |
| Portola Pharmaceuticals, LLC | $30.92 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $29.89 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.20 | 2024 | Zeposia |
| Springworks Therapeutics, INC. | $22.53 | 2025 | Gomekli |
| Impel Pharmaceuticals INC. | $20.00 | 2023 | Trudhesa |
| Corium, LLC | $17.11 | 2023 | Adlarity |
| Microtransponder, INC. | $15.32 | 2025 | |
| Adamas Pharmaceuticals, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.